TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Francesco Morabito; Poeta G. Del; F. R. Mauro; G. Reda; P. Sportoletti; Luca Laurenti; M. Coscia; Y. Herishanu; S. Bossio; M. Varettoni; R. Murru; A. Chiarenza; A. Visentin; A. Condoluci; R. Moia; D. Pietrasanta; G. Loseto; U. Consoli; I. Scortechini; A. G. Recchia; F. M. Rossi; A. Zucchetto; H. Al-Janazreh; E. A. Martino; E. Vigna; G. Tripepi; G. D'Arrigo; S. Galimberti; A. Rago; I. Angeletti; A. Biagi; Giudice I. Del; R. Bomben; A. Neri; G. Fronza; G. Cutrona; O. Jaksic; J. Olivieri; D. Rossi; Raimondo F. Di; A. Cuneo; G. Gaidano; A. Polliack; L. Trentin; R. Foa; M. Ferrarini; V. Gattei; M. Gentile

doi:10.1002/ajh.26235

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Francesco Morabito
, Poeta G. Del
, F. R. Mauro
, G. Reda
, P. Sportoletti
, Luca Laurenti
, M. Coscia
, Y. Herishanu
, S. Bossio
, M. Varettoni
, R. Murru
, A. Chiarenza
, A. Visentin
, A. Condoluci
, R. Moia
, D. Pietrasanta
, G. Loseto
, U. Consoli
, I. Scortechini
, A. G. Recchia

F. M. Rossi, A. Zucchetto, H. Al-Janazreh, E. A. Martino, E. Vigna, G. Tripepi, G. D'Arrigo, S. Galimberti, A. Rago, I. Angeletti, A. Biagi, Giudice I. Del, R. Bomben, A. Neri, G. Fronza, G. Cutrona, O. Jaksic, J. Olivieri, D. Rossi, Raimondo F. Di, A. Cuneo, G. Gaidano, A. Polliack, L. Trentin, R. Foa, M. Ferrarini, V. Gattei, M. Gentile^*

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

n/a

Lingua originale	Inglese
pagine (da-a)	E306-E310
Rivista	American Journal of Hematology
Volume	96
Numero di pubblicazione	8
DOI	https://doi.org/10.1002/ajh.26235
Stato di pubblicazione	Pubblicato - 2019

All Science Journal Classification (ASJC) codes

Ematologia

Keywords

B-Cell
Chromosome Deletion
Chromosomes
Chronic
Human
Humans
Leukemia
Lymphocytic
Molecular Targeted Therapy
Mutation
Pair 17
Prognosis
Retrospective Studies
Risk Factors
Tumor Suppressor Protein p53

Accesso al documento

10.1002/ajh.26235

Altri file e collegamenti

Cita questo

Morabito, F., Del, P. G., Mauro, F. R., Reda, G., Sportoletti, P., Laurenti, L., Coscia, M., Herishanu, Y., Bossio, S., Varettoni, M., Murru, R., Chiarenza, A., Visentin, A., Condoluci, A., Moia, R., Pietrasanta, D., Loseto, G., Consoli, U., Scortechini, I., ... Gentile, M. (2019). TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. American Journal of Hematology, 96(8), E306-E310. https://doi.org/10.1002/ajh.26235

@article{aa55053e37854604bc22bc56e5ed1414,

title = "TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases",

abstract = "n/a",

keywords = "B-Cell, Chromosome Deletion, Chromosomes, Chronic, Human, Humans, Leukemia, Lymphocytic, Molecular Targeted Therapy, Mutation, Pair 17, Prognosis, Retrospective Studies, Risk Factors, Tumor Suppressor Protein p53, B-Cell, Chromosome Deletion, Chromosomes, Chronic, Human, Humans, Leukemia, Lymphocytic, Molecular Targeted Therapy, Mutation, Pair 17, Prognosis, Retrospective Studies, Risk Factors, Tumor Suppressor Protein p53",

author = "Francesco Morabito and Del, \{Poeta G.\} and Mauro, \{F. R.\} and G. Reda and P. Sportoletti and Luca Laurenti and M. Coscia and Y. Herishanu and S. Bossio and M. Varettoni and R. Murru and A. Chiarenza and A. Visentin and A. Condoluci and R. Moia and D. Pietrasanta and G. Loseto and U. Consoli and I. Scortechini and Recchia, \{A. G.\} and Rossi, \{F. M.\} and A. Zucchetto and H. Al-Janazreh and Martino, \{E. A.\} and E. Vigna and G. Tripepi and G. D'Arrigo and S. Galimberti and A. Rago and I. Angeletti and A. Biagi and Del, \{Giudice I.\} and R. Bomben and A. Neri and G. Fronza and G. Cutrona and O. Jaksic and J. Olivieri and D. Rossi and Di, \{Raimondo F.\} and A. Cuneo and G. Gaidano and A. Polliack and L. Trentin and R. Foa and M. Ferrarini and V. Gattei and M. Gentile",

year = "2019",

doi = "10.1002/ajh.26235",

language = "English",

volume = "96",

pages = "E306--E310",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc.",

number = "8",

}

Morabito, F, Del, PG, Mauro, FR, Reda, G, Sportoletti, P, Laurenti, L, Coscia, M, Herishanu, Y, Bossio, S, Varettoni, M, Murru, R, Chiarenza, A, Visentin, A, Condoluci, A, Moia, R, Pietrasanta, D, Loseto, G, Consoli, U, Scortechini, I, Recchia, AG, Rossi, FM, Zucchetto, A, Al-Janazreh, H, Martino, EA, Vigna, E, Tripepi, G, D'Arrigo, G, Galimberti, S, Rago, A, Angeletti, I, Biagi, A, Del, GI, Bomben, R, Neri, A, Fronza, G, Cutrona, G, Jaksic, O, Olivieri, J, Rossi, D, Di, RF, Cuneo, A, Gaidano, G, Polliack, A, Trentin, L, Foa, R, Ferrarini, M, Gattei, V & Gentile, M 2019, 'TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases', American Journal of Hematology, vol. 96, n. 8, pagg. E306-E310. https://doi.org/10.1002/ajh.26235

TY - JOUR

T1 - TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

AU - Morabito, Francesco

AU - Del, Poeta G.

AU - Mauro, F. R.

AU - Reda, G.

AU - Sportoletti, P.

AU - Laurenti, Luca

AU - Coscia, M.

AU - Herishanu, Y.

AU - Bossio, S.

AU - Varettoni, M.

AU - Murru, R.

AU - Chiarenza, A.

AU - Visentin, A.

AU - Condoluci, A.

AU - Moia, R.

AU - Pietrasanta, D.

AU - Loseto, G.

AU - Consoli, U.

AU - Scortechini, I.

AU - Recchia, A. G.

AU - Rossi, F. M.

AU - Zucchetto, A.

AU - Al-Janazreh, H.

AU - Martino, E. A.

AU - Vigna, E.

AU - Tripepi, G.

AU - D'Arrigo, G.

AU - Galimberti, S.

AU - Rago, A.

AU - Angeletti, I.

AU - Biagi, A.

AU - Del, Giudice I.

AU - Bomben, R.

AU - Neri, A.

AU - Fronza, G.

AU - Cutrona, G.

AU - Jaksic, O.

AU - Olivieri, J.

AU - Rossi, D.

AU - Di, Raimondo F.

AU - Cuneo, A.

AU - Gaidano, G.

AU - Polliack, A.

AU - Trentin, L.

AU - Foa, R.

AU - Ferrarini, M.

AU - Gattei, V.

AU - Gentile, M.

PY - 2019

Y1 - 2019

N2 - n/a

AB - n/a

KW - B-Cell

KW - Chromosome Deletion

KW - Chromosomes

KW - Chronic

KW - Human

KW - Humans

KW - Leukemia

KW - Lymphocytic

KW - Molecular Targeted Therapy

KW - Mutation

KW - Pair 17

KW - Prognosis

KW - Retrospective Studies

KW - Risk Factors

KW - Tumor Suppressor Protein p53

KW - B-Cell

KW - Chromosome Deletion

KW - Chromosomes

KW - Chronic

KW - Human

KW - Humans

KW - Leukemia

KW - Lymphocytic

KW - Molecular Targeted Therapy

KW - Mutation

KW - Pair 17

KW - Prognosis

KW - Retrospective Studies

KW - Risk Factors

KW - Tumor Suppressor Protein p53

UR - https://publicatt.unicatt.it/handle/10807/184844

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85106298365&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85106298365&origin=inward

U2 - 10.1002/ajh.26235

DO - 10.1002/ajh.26235

M3 - Article

SN - 0361-8609

VL - 96

SP - E306-E310

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 8

ER -

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo